Contract facts
FederalNo full NAICS 424210 intel page yet. Browse NAICS intelligence
4557846854!POMALYST 4 MG CAPSULE 100S is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $1.7M ($1.7M obligated). Current period of performance ends Aug 9, 2022. Place of performance: CONSHOHOCKEN PA.
Recompete timing
PublicCurrent PoP ended Aug 9, 2022 (1473 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordAmerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DX22F5WPU?
SPE2DX22F5WPU (4557846854!pomalyst 4 MG capsule 100s) is a Dla Troop Support award with a potential value of $1.7M, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2DX22F5WPU?
Dla Troop Support awarded SPE2DX22F5WPU to Amerisourcebergen Drug Corp (potential $1.7M).
Who is the incumbent on SPE2DX22F5WPU?
Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Aug 9, 2022.
When does Amerisourcebergen Drug Corp’s SPE2DX22F5WPU come up for recompete?
SCOUT tracks a period-of-performance end of Aug 9, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.